1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK
  4. CDK Inhibitors

CDK Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

CDK Inhibitors, Antagonists & Activators
Product Name CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Purity
Palbociclib      
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
                      ≥95.0%
Abemaciclib
CDK1/cyclinB1, IC50: 1627 nM
CDK2/cyclinE, IC50: 504 nM
 
Cdk4/cyclin D1, IC50: 2 nM
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
 
CDK9/cyclinT1, IC50: 57 nM
                99.83%
Palbociclib monohydrochloride      
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
                      ≥95.0%
Dinaciclib
CDK1, IC50: 3 nM
CDK2, IC50: 1 nM
   
CDK5, IC50: 1 nM
     
CDK9, IC50: 4 nM
                99.36%
Ribociclib      
CDK4, IC50: 10 nM
 
CDK6, IC50: 39 nM
                      99.93%
BSJ-4-116                    
CDK12, IC50: 6 nM
            99.62%
Manzamine A hydrochloride        
CDK5, IC50: 1.5 μM
                        99.29%
XY028-140      
CDK4
 
CDK6
                      98.28%
Ro-3306
CDK1, Ki: 20 nM
CDK1/cyclinB1, Ki: 35 nM
CDK1/cyclin A, Ki: 110 nM
CDK2/cyclinE, Ki: 340 nM
                              98.54%
Abemaciclib methanesulfonate
CDK1/cyclinB1, IC50: 1627 nM
CDK2/cyclinE, IC50: 504 nM
 
Cdk4/cyclin D1, IC50: 2 nM
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
 
CDK9/cyclinT1, IC50: 57 nM
                ≥98.0%
THZ1            
CDK7, IC50: 3.2 nM
                    ≥98.0%
THZ531            
CDK7, IC50: 8.5 μM
 
CDK9, IC50: 10.5 μM
 
CDK12, IC50: 158 nM
CDK13, IC50: 69 nM
          99.86%
AZD4573                
CDK9, IC50: 4 nM
                99.90%
Seliciclib
cdc2/cyclin B, IC50: 0.65 μM
cdk2/cyclin A, IC50: 0.7 μM
Cdk2/cyclin E2, IC50: 0.7 μM
   
CDK5/p35, IC50: 0.16 μM
                        ≥98.0%
Flavopiridol
CDK1/Cyc B1, IC50: 30 nM
CDK2/Cyc E, IC50: 170 nM
 
CDK4/Cyc D1, IC50: 100 nM
                          99.72%
SR-4835                    
CDK12, IC50: 99 nM
CDK12, Kd: 98 nM
CDK13, Kd: 4.9 nM
          98.46%
Palbociclib isethionate      
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
                      99.99%
Simurosertib                              
Cdc7, IC50: <0.3 nM
  99.07%
Fadraciclib  
CDK2
           
CDK9
                99.78%
NVP-2                
CDK9, IC50: 0.5 nM
                ≥98.0%
Zotiraciclib  
CDK2, IC50: 13 nM
                              99.96%
SNS-032
CDK1, IC50: 480 nM
CDK2, IC50: 38 nM
 
CDK4, IC50: 925 nM
   
CDK7, IC50: 62 nM
 
CDK9, IC50: 4 nM
                99.49%
OTS964 hydrochloride                  
CDK11B, Kd: 40 nM
              99.32%
AZD-5438
cdk1-cyclin B1, IC50: 16 nM
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
 
cdk4-cyclin D1, IC50: 449 nM
cdk5-p25, IC50: 14 nM
cdk6-cyclin D3, IC50: 21 nM
cdk7-cyclin H, IC50: 821 nM
 
cdk9-cyclin T, IC50: 20 nM
                99.55%
AT7519
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
                99.76%
YKL-5-124 TFA  
CDK2, IC50: 1300 nM
       
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
 
CDK9, IC50: 3020 nM
                98.59%
Mevociclib            
CDK7
                    99.27%
Samuraciclib hydrochloride
CDK1, IC50: 1.8 μM
CDK2, IC50: 578 nM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 34 μM
CDK7, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
                99.98%
BSJ-03-123          
CDK6
                      99.45%
GSK 3 Inhibitor IX
Cdk1/cyclin B, IC50: 320 nM
cdk2/cyclin A, IC50: 300 nM
 
Cdk4/cyclin D1, IC50: 10 μM
CDK5/p35, IC50: 80 nM
                        ≥98.0%
THZ1 Hydrochloride            
CDK7, IC50: 3.2 nM
                    98.49%
Kenpaullone
Cdk1/cyclin B, IC50: 0.4 μM
cdk2/cyclin A, IC50: 0.68 μM
CDK2/cyclinE, IC50: 7.5 μM
   
CDK5/p35, IC50: 0.85 μM
                        98.01%
Flavopiridol Hydrochloride
CDK1/Cyc B1, IC50: 30 nM
CDK2/Cyc E, IC50: 170 nM
 
CDK4/Cyc D1, IC50: 100 nM
                          ≥95.0%
AUZ 454  
CDK2(C118L/A144C), Kd: 9.7 nM
CDK2(A144C), Kd: 15.4 nM
CDK2(C118L), Kd: 18.6 nM
CDK2(WT), Kd: 50 nM
CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM
                              99.99%
XL413 hydrochloride                              
Cdc7, IC50: 3.4 nM
  99.82%
AS2863619              
CDK8, IC50: 0.61 nM
           
CDK19, IC50: 4.28 nM
    ≥98.0%
NG 52
cdc2-cyclin B, IC50: 0.34 μM
     
Pho85p, IC50: 2 nM
                        99.97%
(+)-BAY-1251152                
CDK9/CycT1, IC50: 3 nM
                99.66%
CCT-251921              
CDK8, IC50: 2.3 nM
           
CDK19, IC50: 2.6 nM
    99.77%
Wogonin              
CDK8
                  99.98%
MBQ-167                              
Cdc42, IC50: 78 nM
  99.67%
BI-1347              
CDK8, IC50: 1.1 nM
                  99.83%
TG003                                
CLK1, IC50: 20 nM
CLK2, IC50: 200 nM
CLK4, IC50: 15 nM
99.62%
JNJ-7706621
Cdk1/cyclin B, IC50: 9 nM
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
CDK3/Cyclin E, IC50: 58 nM
Cdk4/cyclin D1, IC50: 253 nM
 
CDK6/cyclinD1, IC50: 175 nM
                      99.96%
KB-0742 dihydrochloride                
CDK9/cyclinT1, IC50: 6 nM
                99.63%
CGP60474
CDK1-Cyclin B, IC50: 26 nM
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
 
CDK4/cyclin D, IC50: 216 nM
Cdk5/p25, IC50: 10 nM
 
CDK7/cyclin H, IC50: 200 nM
 
CDK9/cycT, IC50: 13 nM
                98.70%
LDC4297            
CDK7, IC50: 0.13 nM
                    99.14%
SEL120-34A monohydrochloride              
CDK8/CycC, IC50: 4.4 nM
CDK9/cycT, IC50: 1070 nM
         
CDK19/CycC, IC50: 10.4 nM
    99.98%
BMS-265246
CDK1/cycB, IC50: 6 nM
CDK2/Cyc E, IC50: 9 nM
 
CDK4/cycD, IC50: 230 nM
                          99.28%
Ribociclib succinate      
CDK4, IC50: 10 nM
 
CDK6, IC50: 39 nM
                      99.52%
Senexin A              
CDK8, Kd: 0.83 μM
           
CDK19, Kd: 0.31 μM
    99.94%
Roniciclib
Cdk1/cyclin B, IC50: 7 nM
CDK2/cyclinE, IC50: 9 nM
 
CDK4/cyclin D, IC50: 11 nM
   
CDK7/Cyclin H/MAT1, IC50: 25 nM
 
CDK9/cyclinT1, IC50: 5 nM
                98.89%
Milciclib
cyclin B/CDK1, IC50: 398 nM
cyclin A/CDK2, IC50: 45 nM
cyclin E/CDK2, IC50: 363 nM
 
cyclin D1/CDK4, IC50: 160 nM
   
cyclin H/CDK7, IC50: 150 nM
                    99.89%
CVT-313
Cdk1/cyclin B, IC50: 4.2 μM
cdk2/cyclin A, IC50: 0.5 μM
 
Cdk4/cyclin D1, IC50: 215 μM
                          99.76%
(R)-CR8 trihydrochloride
CDK1/cyclinB1, IC50: 0.09 μM
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
   
Cdk5/p25, IC50: 0.11 μM
 
CDK7/cyclin H, IC50: 1.1 μM
 
CDK9/Cyclin T, IC50: 0.18 μM
                99.02%
Ribociclib hydrochloride      
CDK4, IC50: 10 nM
 
CDK6, IC50: 39 nM
                      99.95%
CLK-IN-T3                                
CLK1, IC50: 0.67 nM
CLK2, IC50: 15 nM
CLK3, IC50: 110 nM
98.40%
CDK12-IN-3                    
CDK12, IC50: 491 nM
            98.22%
PHA-767491 hydrochloride
CDK1, IC50: 250 nM
CDK2, IC50: 240 nM
   
CDK5, IC50: 460 nM
     
CDK9, IC50: 34 nM
                99.91%
KH-CB19                                
CLK1, IC50: 19.7 nM
CLK3, IC50: 530 nM
99.66%
R547
Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC50: 0.2 nM
CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC50: 0.1 nM
CDK2/cyclinE, IC50: 0.4 nM
CDK3/Cyclin E, IC50: 0.8 nM
CDK4/cyclin D, Ki: 1 nM
CDK5/p35, IC50: 0.1 nM
cdk6/cyclin D3, IC50: 4 nM
CDK7/cyclin H, IC50: 171 nM
                    99.66%
THZ2
CDK1, IC50: 96.9 nM
CDK2, IC50: 222 nM
   
CDK5, IC50: 134 nM
 
CDK7, IC50: 13.9 nM
CDK8, IC50: 6830 nM
CDK9, IC50: 194 nM
                ≥95.0%
PHA-793887
Cdk1/cyclin B, IC50: 60 nM
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
 
Cdk4/cyclin D1, IC50: 62 nM
Cdk5/p25, IC50: 5 nM
 
CDK7/cyclin H, IC50: 10 nM
 
CDK9/cyclinT1, IC50: 138 nM
                99.25%
Trilaciclib hydrochloride      
Cdk4/cyclin D1, IC50: 1 nM
 
cdk6/cyclin D3, IC50: 4 nM
                      99.24%
FN-1501  
cdk2/cyclin A, IC50: 2.47 nM
 
Cdk4/cyclin D1, IC50: 0.85 nM
 
CDK6/cyclinD1, IC50: 1.96 nM
                      99.71%
Atuveciclib
CDK1/CycB(h), IC50: 1100 nM
CDK2/CycE(h), IC50: 1000 nM
CDK3/CycE(h), IC50: 890 nM
 
CDK5/p35(h), IC50: 1600 nM
     
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
                99.20%
CDK2-IN-4
Cdk1/cyclin B, IC50: 86 μM
cdk2/cyclin A, IC50: 44 nM
                              ≥97.0%
Purvalanol A
cdc2-cyclin B, IC50: 4 nM
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
 
cdk4-cyclin D1, IC50: 850 nM
cdk5-p35, IC50: 75 nM
                        99.11%
CLK1-IN-1                                
CLK1, IC50: 2 nM
99.05%
ON123300      
Cdk4/cyclin D1, IC50: 3.9 nM
 
CDK6/cyclinD1, IC50: 9.82 nM
                      99.34%
Riviciclib hydrochloride
CDK1-Cyclin B, IC50: 0.079 μM
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
   
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
                98.33%
Cucurbitacin E
cyclin B1/CDC2
                                99.92%
LDC000067
cdk1-cyclin B1, IC50: 5513 nM
cdk2-cyclin A, IC50: 2441 nM
 
cdk4-cyclin D1, IC50: 9242 nM
       
CDK9- Cyclin T1, IC50: 44 nM
                98.58%
Abemaciclib metabolite M2      
CDK4, IC50: 1-3 nM
 
CDK6, IC50: 1-3 nM
                      99.82%
Abemaciclib metabolite M20      
CDK4
 
CDK6
                      98.24%
MSC2530818              
CDK8, IC50: 2.6 nM
                  99.69%
FMF-04-159-2  
CDK2, IC50: 256 nM (in NanoBRET assay)
                   
CDK14/Cyclin Y, IC50: 39.6 nM (in NanoBRET assay)
        99.34%
CP-10          
CDK6, DC50: 2.1 nM
                      98.03%
Bisindolylmaleimide X hydrochloride  
CDK2, IC50: 200 nM
                              98.53%
ML167                                
CLK4, IC50: 136 nM
CLK1, IC50: 1522 nM
CLK2, IC50: 1648 nM
98.62%
LY2857785            
CDK7, IC50: 0.246 μM
CDK8, IC50: 0.016 μM
CDK9, IC50: 0.011 μM
                98.88%
CDK5 inhibitor 20-223  
CDK2, IC50: 6.0 nM
   
CDK5, IC50: 8.8 nM
                        99.64%
PF 477736
CDK1, Ki: 9.9 μM
                                99.21%
BS-181 hydrochloride
CDK1/cycB, IC50: 8.1 μM
CDK2/Cyc E, IC50: 0.88 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
 
CDK9/cycT, IC50: 4.2 μM
                ≥99.0%
CDK12-IN-E9  
cdk2/cyclin A, IC50: 932 nM
       
CDK7/Cyclin H/MNAT1, IC50: 1210 nM
 
CDK9/cyclinT1, IC50: 23.9 nM
                99.20%
CDK9-IN-2                
CDK9, IC50: 5 nM (H929 multiple myeloma cell line)
                99.84%
Purvalanol B
cdc2/cyclin B, IC50: 6 nM
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
   
CDK5/p35, IC50: 6 nM
                        ≥97.0%
CDK9-IN-1                
CDK9/CycT1, IC50: 39 nM
                98.52%
PROTAC CDK9 Degrader-1                
CDK9
                98.34%
BSJ-03-204      
CDK4/D1, IC50: 26.9 nM
 
CDK6/D1, IC50: 10.4 nM
                      98.34%
CDKI-73
CDK1, IC50: 8.17 nM
CDK1, Ki: 4 nM
CDK2, IC50: 3.27 nM
CDK2, Ki: 3 nM
 
CDK4, IC50: 8.18 nM
 
CDK6, IC50: 37.68 nM
CDK7, IC50: 134.26 nM
CDK7, Ki: 91 nM
 
CDK9, IC50: 5.78 nM
CDK9, Ki: 4 nM
                99.58%
SU9516
CDK1, IC50: 40 nM
CDK2, IC50: 22 nM
 
CDK4, IC50: 200 nM
                          99.83%
CC-671                                
CLK2, IC50: 0.006 μM
99.08%
CKI-7 free base                              
Cdc7
  99.31%
AS2863619 free base              
CDK8, IC50: 0.61 nM
           
CDK19, IC50: 4.28 nM
    ≥98.0%
CDK-IN-2                
CDK9/cyclinT1, IC50: 8 nM
                98.82%
YKL-5-124  
CDK2, IC50: 1300 nM
       
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
 
CDK9, IC50: 3020 nM
                98.03%
ON-013100      
Cdk4/cyclin D1
                          98.23%
Atuveciclib Racemate                
CDK9
                ≥98.0%
TL12-186  
cdk2/cyclin A, IC50: 73 nM
           
CDK9/cyclinT1, IC50: 55 nM
                ≥99.0%
Longdaysin            
CDK7, IC50: 29 μM
                    99.92%
AT7519 Hydrochloride
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
                99.29%
JH-XI-10-02              
CDK8, IC50: 159 nM
                  98.18%
BSJ-04-132      
CDK4/D1, IC50: 50.6 nM
 
CDK6/D1, IC50: 30 nM
                      98.08%
(-)-BAY-1251152                
CDK9
                99.81%
AMG 925
CDK1, IC50: 1.9 μM
CDK2, IC50: 375 nM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 8 nM
                      98.24%
PROTAC CDK2/9 Degrader-1  
CDK2, DC50: 62 nM
           
CDK9, DC50: 33 nM
                99.85%
Voruciclib
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
   
CDK4/Cyc D1, Ki: 3.96 nM
 
CDK6/cycD1, Ki: 2.92 nM
   
CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM
                99.52%
NU6102
Cdk1/cyclin B, IC50: 9.5 nM
CDK2/cyclin A3, IC50: 5.4 nM
 
CDK4, IC50: 1.6 μM
                          ≥95.0%
hSMG-1 inhibitor 11j
CDK1, IC50: 32 μM
CDK2, IC50: 7.1 μM
                              99.81%
Voruciclib hydrochloride
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
   
CDK4/Cyc D1, Ki: 3.96 nM
 
CDK6/cycD1, Ki: 2.92 nM
   
CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM
                98.20%
(R)​-​CR8
Cdk1/cyclin B, IC50: 0.09 μM
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
   
Cdk5/p25, IC50: 0.11 μM
 
CDK7/cyclin H, IC50: 1.1 μM
 
CDK9/Cyclin T, IC50: 0.18 μM
                ≥98.0%
Lerociclib dihydrochloride
CDK1/cyclinB1, IC50: 2.4 μM
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
 
CDK9/Cyclin T, IC50: 28 nM
                99.74%
K00546
Cdk1/cyclin B, IC50: 0.6 nM
cdk2/cyclin A, IC50: 0.5 nM
                           
CLK1, IC50: 8.9 nM
CLK3, IC50: 29.2 nM
98.78%
LSN3106729 hydrochloride      
CDK4
 
CDK6
                      99.01%
LY3177833                              
Cdc7, IC50: 3.3 nM
  99.76%
CDK9-IN-7      
CDK4/cyclin D, IC50: 148 nM
 
CDK6/cyclinD, IC50: 145 nM
   
CDK9/cyclinT1, IC50: 11 nM
                99.81%
CDK9-IN-8                
CDK9, IC50: 12 nM
                99.06%
NU6140
CDK1-Cyclin B, IC50: 6.6 μM
cdk2-cyclin A, IC50: 0.41 μM
 
CDK4-Cyclin D, IC50: 5.5 μM
cdk5-p25, IC50: 15 μM
 
cdk7-cyclin H, IC50: 3.9 μM
                    ≥99.0%
SY-5609  
CDK2, Ki: 390 nM
       
CDK7, Kd: 0.059 nM
 
CDK9, Ki: 290 nM
 
CDK12, Ki: 78 nM
            99.66%
BS-181
CDK1/cycB, IC50: 8.1 μM
CDK2/Cyc E, IC50: 0.88 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
 
CDK9/cycT, IC50: 4.2 μM
                98.10%
Olomoucine  
cdk2-cyclin A, IC50: 7 μM
cdk2-cyclin E, IC50: 7 μM
                              ≥98.0%
BGG463  
CDK2
                              ≥98.0%
PNU112455A hydrochloride  
CDK2, Km: 3.6 μM
   
CDK5, Km: 3.2 μM
                        99.62%
Garcinone C            
CDK7
                    ≥95.0%
Ribociclib succinate hydrate      
CDK4, IC50: 10 nM
 
CDK6, IC50: 39 nM
                      99.96%
MC180295
CDK1-Cyclin B, IC50: 138 nM
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
CDK3-Cyclin E, IC50: 399 nM
CDK4-Cyclin D, IC50: 112 nM
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
cdk6-cyclin D3, IC50: 712 nM
CDK7-CycH/MAT1, IC50: 555 nM
 
CDK9- Cyclin T1, IC50: 5 nM
                98.41%
CDK7-IN-1            
CDK7, IC50: 100 nM
                    98.91%
Palbociclib D8      
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
                      99.84%
BRD6989              
CDK8, IC50: ~200 nM
recombinant CDK8, IC50: ~0.5 μM
           
recombinant CDK19, IC50: >30 μM
    99.85%
Nimbolide      
CDK4
 
CDK6
                      ≥97.0%
NVP-LCQ195
Cdk1/cyclin B, IC50: 2 nM
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
CDK3/Cyclin E, IC50: 42 nM
 
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
cdk6/cyclin D3, IC50: 187 nM
CDK7/Cyclin H/MAT1, IC50: 3564 nM
 
CDK9/cyclinT1, IC50: 15 nM
                99.80%
JSH-150
Cdk1/cyclin B, IC50: 1.34 μM
cdk2/cyclin A, IC50: 2.86 μM
   
Cdk5/p25, IC50: 4.64 μM
 
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
 
CDK9/cyclinT1, IC50: 1 nM
     
CDK14/Cyclin Y, IC50: 1.68 μM
CDK16/Cyclin Y, IC50: 292 nM
      98.36%
SEL120-34A HCl              
CDK8/CycC, IC50: 4.4 nM
CDK9/cycT, IC50: 1070 nM
         
CDK19/CycC, IC50: 10.4 nM
    99.98%
EHT 5372                                
CLK1, IC50: 22.8 nM
CLK2, IC50: 88.8 nM
CLK4, IC50: 59.0 nM
Casein Kinase inhibitor A51            
CDK7, Kd: 1.3 nM
 
CDK9, Kd: 4 nM
                98.42%
IV-361  
CDK2, Ki: ≥1000 nM
       
CDK7, Ki: ≤50 nM
                   
XY028-133      
CDK4
 
CDK6
                      98.03%
Samuraciclib trihydrochloride
CDK1, IC50: 1.8 μM
CDK2, IC50: 578 nM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 31 μM
CDK7, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
                99.08%
NU6027
CDK1, Ki: 2.5 μM
CDK2, Ki: 1.3 μM
                              99.35%
Desmethylglycitein
CDK1
CDK2
                              ≥95.0%
NU2058
CDK1, IC50: 26 μM
CDK2, IC50: 17 μM
CDK2, Ki: 12 μM
                              99.01%
CDK8-IN-1              
CDK8, IC50: 3 nM
                  98.62%
CAN508
Cdk1/cyclin B, IC50: 44 μM
CDK2/cyclinE, IC50: 20 μM
cdk2/cyclin A, IC50: 69 μM
 
Cdk4/cyclin D1, IC50: 13.5 μM
   
CDK7/cyclin H, IC50: 26 μM
 
CDK9/cyclinT1, IC50: 0.35 μM
                99.91%
CDK4/6-IN-2      
CDK4, IC50: 2.7 nM
 
CDK6, IC50: 16 nM
                      99.82%
Alsterpaullone
Cdk1/cyclin B, IC50: 35 nM
cdk2/cyclin A, IC50: 15 nM
CDK2/Cyc E, IC50: 200 nM
   
CDK5/p35, IC50: 40 nM
                        ≥98.0%
FIT-039                
CDK9/cyclinT1, IC50: 5.8 μM
                ≥98.0%
TC11
CDK1
                                98.04%
AMG 925 HCl
CDK1, IC50: 1.9 μM
CDK2, IC50: 375 nM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 8 nM
                      98.01%
5-Iodo-indirubin-3'-monoxime
Cdk1/cyclin B, IC50: 25 nM
     
Cdk5/p25, IC50: 20 nM
                        99.50%
SEL120-34A              
CDK8/CycC, IC50: 4.4 nM
CDK9/cycT, IC50: 1070 nM
         
CDK19/CycC, IC50: 10.4 nM
   
XL413                              
Cdc7, IC50: 3.4 nM
 
AT7519 TFA
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
                98.16%
PHA-767491
CDK1, IC50: 250 nM
CDK2, IC50: 240 nM
   
CDK5, IC50: 460 nM
     
CDK9, IC50: 34 nM
               
Samuraciclib
CDK1, IC50: 1.8 μM
CDK2/cycE1, IC50: 578 nM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 34 μM
CDK7/CycH/MAT1, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
               
CDK4/6-IN-3
CDK1, Ki: 110 nM
   
CDK4, Ki: 0.3 nM
 
CDK6, Ki: 2.2 nM
                     
FN-1501-propionic acid  
CDK2
           
CDK9
               
CDK8/19-IN-1              
CDK8/CycC, IC50: 0.46 nM
CDK9, IC50: 270 nM
         
CDK19/CycC, IC50: 0.99 nM
   
CDK9-IN-9  
CDK2, IC50: 155 nM
           
CDK9, IC50: 1.8 nM
               
CPS2  
CDK2, IC50: 24 nM
                             
IIIM-290  
CDK2/A, IC50: 90 nM
           
CDK9/T1, IC50: 94 nM
               
CDK12-IN-2  
CDK2, IC50: >100 μM
       
CDK7, IC50: >10 μM
CDK7, IC50: >10 μM
 
CDK9, IC50: 16 μM
 
CDK12, IC50: 52 nM
           
Ipivivint
CDK1, IC50: 1.4 μM
CDK2, IC50: 0.002 μM
CDK3, IC50: 0.022 μM
                           
Riviciclib
CDK1-Cyclin B, IC50: 0.079 μM
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
   
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
               
OTS964                  
CDK11B, Kd: 40 nM
             
CDK6/9-IN-1          
CDK6, IC50: 40.5 nM
   
CDK9, IC50: 39.5 nM
               
Avotaciclib
CDK1
                               
Dalpiciclib      
CDK4, IC50: 12.4 nM
 
CDK6, IC50: 9.9 nM
                     
Lerociclib
CDK1/cyclinB1, IC50: 2.4 μM
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
 
CDK9/Cyclin T, IC50: 28 nM
               
CDK7-IN-2 hydrochloride hydrate            
CDK7
                   
BS-181 dihydrochloride  
CDK2, IC50: 880 nM
   
CDK5, IC50: 3000 nM
 
CDK7, IC50: 21 nM
 
CDK9, IC50: 4200 nM
               
CKI-7                              
Cdc7
 
Aloisine A
CDK1/cyclinB, IC50: 0.15 μM
CDK2/cyclinA, IC50: 0.12 μM
CDK2/cyclinE, IC50: 0.4 μM
   
CDK5/p35, IC50: 0.16 μM
                       
CDK9-IN-11                
CDK9
               
Bohemine  
CDK2/cyclinE, IC50: 4.6 μM
cdk2/cyclin A, IC50: 83 μM
           
CDK9/cyclinT1, IC50: 2.7 μM
                ≥98.0%
PROTAC CDK9 degrader-2                
CDK9, IC50: 17 μM (MCF-7 cells)
               
CDK4/6-IN-6      
Cdk4/cyclin D1, Ki: 0.6 nM
 
cdk6/cyclin D3, Ki: 13.9 nM
                     
CDK12-IN-5  
CDK2/cyclinE, IC50: 173 μM
           
CDK9/cyclinT1, IC50: 127 μM
 
CDK12, IC50: 23.9 nM
           
NSC 625987      
CDK4/D1, IC50: 0.2 μM
                         
CDK5-IN-1        
CDK5
                       
CDK12-IN-6  
CDK2/cyclinE, IC50: >20 μM
           
CDK9/cyclinT1, IC50: >20 μM
 
CDK12, IC50: 1.19 μM
           
Cdk1/2 Inhibitor III
Cdk1/cyclin B, IC50: 2.1 μM
                               
3-Methylthienyl-carbonyl-JNJ-7706621
CDK1/cyclinB, IC50: 6.4 nM
CDK2/cyclinA, IC50: 2 nM
 
CDK4, IC50: 0.11 μM
                         
CDK12-IN-4  
CDK2/cyclinE, IC50: >20 μM
           
CDK9/cyclinT1, IC50: >20 μM
 
CDK12, IC50: 0.641 μM
           
Casein Kinase inhibitor A86            
CDK7, Kd: 0.31 nM
 
CDK9, Kd: 5.4 nM
               
Indirubin-3'-monoxime-5-sulphonic acid
CDK1, IC50: 5 nM
     
CDK5, IC50: 7 nM
                       
Indirubin-5-sulfonate
Cdk1/cyclin B, IC50: 55 nM
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
 
Cdk4/cyclin D1, IC50: 300 nM
CDK5/p35, IC50: 65 nM
                       
CDK9-IN-10                
CDK9
               
hSMG-1 inhibitor 11e
CDK1, IC50: 32 μM
CDK2, IC50: 7.1 μM
                              99.18%